The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures

Evelien Moorkens, Brian Godman, Isabelle Huys, Iris Hoxha, Admir Malaj, Simon Keuerleber, Silvia Stockinger, Sarah Mörtenhuber, Maria Dimitrova, Konstantin Tachkov, Luka Vončina, Vera Vlahović Palčevski, Gnosia Achniotou, Juraj Slabý, Leona Popelková, Kateřina Kohoutová, Dorthe Bartels, Ott Laius, Jaana E. Martikainen, Gisbert W. SelkeVasileios Kourafalos, Einar Magnússon, Rannveig Einarsdóttir, Roisín Adams, Roberta Joppi, Eleonora Allocati, Arianit Jakupi, Anita Viksna, Ieva Greičiūtė-Kuprijanov, Patricia Vella Bonanno, Vincent Suttorp, Øyvind Melien, Robert Plisko, Ileana Mardare, Dmitry Meshkov, Tanja Novakovic, Jurij Fürst, Corinne Zara, Vanda Marković-Peković, Nataša Grubiša, Gustaf Befrits, Robert Puckett, Arnold G. Vulto*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

48 Citations (Scopus)
24 Downloads (Pure)

Fingerprint

Dive into the research topics of 'The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures'. Together they form a unique fingerprint.

Agricultural and Biological Sciences